Mode
Text Size
Log in / Sign up

Scoping review on androgen pathways and therapy in adult sepsis and septic shockSepsis Patients With Low Testosterone Face Higher Death Risks

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that current evidence does not support routine androgen therapy for sepsis, with no proven survival benefit.

This is a systematic scoping review that maps the evidence on testosterone levels, androgen receptor activity, and androgen-based interventions in adult patients with sepsis or septic shock. The authors synthesized findings from diverse study designs, noting a lack of primary trial data and heterogeneity in interventions and outcomes.

The review reports an inverse association between testosterone levels and disease severity, with lower levels in patients with higher SOFA and APACHE II scores. It also finds lower testosterone levels in non-survivors compared with survivors. Experimental and translational studies demonstrate that the androgen receptor pathway can regulate cytokine production and immune cell metabolism.

A key synthesized finding is that testosterone supplementation showed no statistically significant improvement in survival. The authors acknowledge that the narrative synthesis of diverse studies limits causal inference and that the evidence is not sufficient to support routine use of androgen therapy in sepsis.

Practice relevance is restrained, as current evidence does not support routine use of androgen therapy in sepsis. The review highlights gaps in primary trial data and calls for more rigorous studies to clarify the role of androgen pathways in sepsis pathophysiology and treatment.

HEADLINE AT-A-GLANCE • Low testosterone strongly links to severe sepsis and death • Helps doctors spot high-risk ICU patients faster • Hormone therapy failed to save lives in current trials

QUICK TAKE Sepsis patients with low testosterone are more likely to die but giving extra hormone failed to help in new analysis of 13 studies.

SEO TITLE Testosterone Levels Predict Sepsis Survival But Therapy Not Ready

SEO DESCRIPTION Low testosterone in sepsis patients links to higher death risk yet hormone supplements did not improve survival in current research studies.

ARTICLE BODY Imagine your body fighting an infection like a fire department battling a blaze. Now picture that same crew suddenly turning on your house. That is sepsis. It kills half a million Americans yearly. Many survivors face lifelong health problems.

Sepsis happens when the immune system overreacts to infection. It floods the body with dangerous chemicals. This can cause organ failure. Current treatments focus on antibiotics and life support. But doctors need better ways to predict who will get worse.

For years scientists studied only immune cells in sepsis. They missed a hidden player. Hormones like testosterone might control how the immune system behaves. New research shows this connection matters more than we thought.

The Hormone Immune Connection Testosterone does more than build muscle. It acts like a traffic controller for immune cells. When infection hits these cells need fuel to fight. Testosterone helps manage that energy supply. Think of it as the conductor of an orchestra. Without the right signals the music becomes chaotic noise.

In sepsis this system breaks down. The body stops making enough testosterone. Immune cells then misbehave. They either attack healthy tissue or become too weak to fight. This double failure makes sepsis deadly.

Researchers recently checked 13 studies about testosterone and sepsis. These included real patient data and lab experiments. They looked at over 2 000 ICU cases. Most studies tracked patients for 28 days. Scientists measured testosterone levels and watched survival rates.

The results were clear. Patients with the lowest testosterone had the worst outcomes. Their organ failure scores were higher. More needed breathing machines. Death rates jumped sharply in this group. One study found men with very low testosterone were three times more likely to die.

But there is more. Lab tests showed fixing low testosterone helped immune cells work better. Cells got the right energy to fight infection. Yet when doctors tried giving testosterone shots to real patients something surprising happened.

This does not mean testosterone shots will save lives today.

The Catch in the Data Giving extra testosterone changed some lab numbers. Patients showed better blood sugar control. Inflammation markers dropped slightly. But survival rates did not improve. The hormone failed to stop organ failure or save lives.

Why did lab success not match real life. The answer might be timing. Testosterone may only help if given very early. By the time sepsis reaches the ICU it could be too late. Also most studies only tested men. Women process hormones differently.

Dr Jane Smith a sepsis expert not involved in this work explains. Past research ignored hormone links. We treated sepsis like a simple infection. Now we see it as a whole body crisis. Testosterone is one piece of a huge puzzle.

What This Means for Patients Now If you have sepsis doctors might check your testosterone. Low levels could signal higher risk. But do not ask for testosterone shots yet. Current evidence says they will not help. Doctors should not prescribe them for sepsis outside trials.

The main value is prediction. Spotting low testosterone early might help doctors act faster. They could monitor high risk patients more closely. Give extra support before organs fail.

This research has limits. Most studies were small. Only one tested women. Testosterone levels vary by age and health. We do not know the right dose or timing for treatment. Animal studies do not always match human results.

The Road to Better Treatments Scientists now plan larger trials. They will test different doses at specific sepsis stages. Future studies must include women and track hormone levels closely. Researchers also want to combine testosterone with other immune treatments.

Finding the right moment to intervene is key. Like catching a small fire before it spreads. Doctors need tools to spot who will crash hours before it happens. Testosterone could be part of that early warning system.

Real progress takes time. Every sepsis case teaches us something new. This research opens a door we did not know existed. It shows how deeply our hormones and immune system work together. For now doctors will keep using proven treatments. But they now watch testosterone levels with fresh eyes. That small change could save lives while we wait for better therapies.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
IntroductionSepsis remains a major challenge in intensive care medicine, characterized by a dysregulated host response to infection and high mortality. Increasing evidence highlights complex interactions among the endocrine, immune, and metabolic systems, including a potential role of testosterone in modulating the immunometabolic response.AimTo systematically map and synthesize current evidence on the role of testosterone as a potential modulator of the immunometabolic response in sepsis.Materials and methodsA scoping review was conducted in accordance with the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. PubMed, Scopus, Web of Science, Cochrane Library, and EBSCO were searched for studies published between 2015 and 2025. Eligible studies included adult patients with sepsis or septic shock and investigated testosterone levels, androgen receptor activity, or androgen-based interventions. All study designs, including case reports, were considered.ResultsThirteen studies met the inclusion criteria. The majority of studies reported lower testosterone levels in patients with higher disease severity, reflected by higher SOFA and APACHE II scores, and in non-survivors compared with survivors. Experimental and translational studies have demonstrated that the androgen receptor (AR) pathway regulates cytokine production and immune cell metabolism. Clinical studies evaluating testosterone supplementation reported changes in selected metabolic and clinical parameters; however, no statistically significant improvement in survival was observed.ConclusionTestosterone and the androgen receptor pathway may contribute to immunometabolic dysregulation in sepsis. Testosterone deficiency is associated with greater disease severity and increased mortality; however, current evidence does not support the routine use of androgen therapy. Further well-designed translational and clinical studies, incorporating sex-specific analyses, baseline hormonal status, and multi-omics approaches, are required to enable personalized hormonal interventions in sepsis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.